Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07505004 · ClinicalTrials.gov registry record · Phase 3
Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures
A Phase 3 study, sponsored by Praxis Precision Medicines.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
NCT07505004 is a Phase 3 study that is actively recruiting participants, run by Praxis Precision Medicines. The registered enrollment target is 300 participants.
The verdict
NCT07505004, a Phase 3 study, is actively recruiting participants, sponsored by Praxis Precision Medicines.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
Study Summary
A multicenter, double-blind, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of vormatrigine in adults with focal seizures (POWER2)
Interventions
- DRUG Placebo
- DRUG 40 mg/day vormatrogine for 12 weeks
- DRUG 30 mg/day vormatrogine for 12 weeks
- DRUG 20 mg/day vormatrogine for 12 weeks
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2026-01-29 |
| Est. Completion | 2027-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07505004
The ClinicalTrials.gov registry entry for NCT07505004 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Praxis Precision Medicines, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT07505004 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07505004 about?
NCT07505004 is a clinical study titled "Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures". A multicenter, double-blind, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of vormatrigine in adults with focal seizures (POWER2)
What is the current status of trial NCT07505004?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2026-01-29. Estimated completion is 2027-05.
What interventions are being tested in trial NCT07505004?
The interventions under investigation include: Placebo (DRUG), 40 mg/day vormatrogine for 12 weeks (DRUG), 30 mg/day vormatrogine for 12 weeks (DRUG), 20 mg/day vormatrogine for 12 weeks (DRUG).
Who is sponsoring clinical trial NCT07505004?
This trial is sponsored by Praxis Precision Medicines, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.